[Trends in the development of immunomodulators based physiopathological mechanisms of various types of hypersensitivities].
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D003545:Cysteine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006046:Gold / Q000627:therapeutic use; D006967:Hypersensitivity / Q000276:immunology* / Q000628:therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy; D007978:Levamisole / Q000627:therapeutic use; D008297:Male; D051379:Mice; D062367:ortho-Aminobenzoates / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D062367:ortho-Aminobenzoates; D007978:Levamisole; D006046:Gold; C015735:lobenzarit; D003545:Cysteine; C026535:bucillamine